BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3422964)

  • 1. [Clinico-pharmacological approach to rifampicin and isoniazid dosage].
    Karkishchenko NN; Khoron'ko VV; Vorob'ev VS; Anisimova NB; Chubarian VT
    Probl Tuberk; 1987; (9):31-4. PubMed ID: 3422964
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifapentine for the treatment of tuberculosis: is it all it can be?
    Gordin FM
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significance of the acetylator phenotype and initial oral/intravenous rifampicin administration in the treatment of tuberculosis].
    Loos U; Musch E; Schwabe HK
    Pneumologie; 1990 Feb; 44 Suppl 1():488-9. PubMed ID: 2367445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
    Dubra F
    Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
    [No Abstract]   [Full Text] [Related]  

  • 5. Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis.
    Garg SK; Dhand R; Malik SK; Kalra S; Gupta PH; Jha VK; Shukla VK; Lal R
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):417-20. PubMed ID: 3220617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
    Schaberg T; Lode H
    Z Gesamte Inn Med; 1991 Jun; 46(8):276-9. PubMed ID: 1897286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the pharmacokinetics of rifampicin I: Influence of dosage and duration of treatment with intermittent administration.
    Iwainsky H; Winsel K; Werner E; Eule H
    Scand J Respir Dis; 1974; 55(4):229-36. PubMed ID: 4438983
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum concentration of isoniazid following administration of the drug alone and in combination with rifampicin in patients of pulmonary tuberculosis.
    Singhal KC; Rathi R; Kishore K; Varshney SC; Varshney DP
    Indian J Physiol Pharmacol; 1986; 30(1):115-7. PubMed ID: 3818028
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical effect of rifampicin-ethambutol isoniazid on untreated pulmonary tuberculosis.
    Konno K; Oizumi K; Yamada S; Ogata K; Sato M
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):68-72. PubMed ID: 4649624
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rifampicin pharmacokinetics in patients with destructive pulmonary tuberculosis].
    Karkishchenko NN; Vorob'ev VS; Khoron'ko VV; Anisimova NB; Chubarian VT
    Vrach Delo; 1988 Dec; (12):72-3. PubMed ID: 3245176
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
    Musch E; Loos U; Schwabe HK
    Pneumologie; 1990 Feb; 44 Suppl 1():486-7. PubMed ID: 2367444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous rifampicin therapy in open tuberculosis].
    Loos U; Musch E; Mackes KG; Reetz KP; Gläser R; Schwabe HK; Hengstmann J; Eichelbaum M
    Med Welt; 1983 Jun; 34(24):701-3. PubMed ID: 6888237
    [No Abstract]   [Full Text] [Related]  

  • 13. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
    Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
    Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazed for primary treatment: the influence of various factors on the frequency of side-effects.
    Eule H; Werner E; Winsel K; Iwainsky H
    Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4470836
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacokinetic bases for the drug-free prevention of drug-induced hepatitis in pulmonary tuberculosis patients].
    Koriakin VA; Sokolova GB; Ziia AV; Zeliger LR; Ivleva AIa
    Ter Arkh; 1987; 59(7):75-7. PubMed ID: 3672366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A triple regimen of streptomycin, isoniazid and ethambutol or rifampicin, isoniazid and ethambutol in untreated cases of pulmonary tuberculosis. 3.
    Oka S; Sasaki M; Kobayashi T; Matsuda T
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):84-8. PubMed ID: 4649627
    [No Abstract]   [Full Text] [Related]  

  • 18. A Singapore study of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis (1).
    Lee SK
    Bull Int Union Tuberc; 1976; 51(1):109-13. PubMed ID: 1030269
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.